Can Latuda Cause Seizures?
Yes, Latuda (lurasidone) can cause seizures and should be used cautiously in patients with a history of seizures or conditions that lower the seizure threshold. 1
Seizure Risk Profile
The FDA label explicitly states that lurasidone should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (e.g., Alzheimer's dementia), and notes that conditions lowering seizure threshold may be more prevalent in patients 65 years or older 1.
Clinical Trial Data
In adult schizophrenia trials, seizures/convulsions occurred in 0.1% (2/1508) of Latuda-treated patients compared to 0.1% (1/708) of placebo patients 1.
In bipolar depression studies (both monotherapy and adjunctive therapy), no patients experienced seizures/convulsions in the controlled trials 1.
However, these low rates should be interpreted with caution, as patients with active seizure disorders are typically excluded from clinical trials.
Comparative Risk Among Atypical Antipsychotics
Recent real-world pharmacovigilance data from 2026 analyzing over 9,000 reports shows that lurasidone has one of the lowest seizure reporting signals among atypical antipsychotics 2. The study found that:
- Ziprasidone showed the strongest seizure association (ROR025 = 3.21)
- Quetiapine (ROR025 = 2.62), clozapine (ROR025 = 2.58), olanzapine (ROR025 = 2.53), and aripiprazole (ROR025 = 2.05) showed moderate-to-high signals
- Lurasidone, along with risperidone and paliperidone, exhibited comparatively lower seizure signals 2
This suggests that while seizures can occur with lurasidone, the risk appears lower than with several other commonly used atypical antipsychotics.
Clinical Implications and Monitoring
When to Exercise Caution:
- History of seizure disorder (especially if not on anticonvulsants)
- Conditions lowering seizure threshold: Alzheimer's dementia, brain lesions, metabolic disturbances
- Elderly patients (≥65 years) who have higher prevalence of seizure-predisposing conditions
- Concurrent medications that lower seizure threshold
Practical Management:
- Close observation is required when prescribing to patients with seizure history 1
- Ensure patients with known seizure disorders are on appropriate anticonvulsant therapy
- Monitor for new-onset seizure activity, particularly during dose titration
- Consider lower starting doses (20 mg/day) in high-risk patients
Important Caveats
The pharmacovigilance study identified a significant inverse correlation between the 5-HT1A/D2 receptor affinity ratio and seizure risk (rs = -0.79, p = 0.036), suggesting a potential pharmacodynamic mechanism for seizure risk that varies among antipsychotics 2. Lurasidone's relatively favorable receptor profile may contribute to its lower seizure signal compared to other agents.
One case report documented successful use of lurasidone in a patient with comorbid epilepsy and treatment-resistant bipolar disorder without seizure exacerbation 3, though this single case should not override the general caution advised in the FDA label.
Bottom line: While lurasidone can cause seizures, real-world data suggests it carries a lower risk than many other atypical antipsychotics. Use cautiously in predisposed patients with close monitoring, but it may actually be a preferable choice when an antipsychotic is needed in patients with seizure risk factors.